Previous close | 49.74 |
Open | 49.50 |
Bid | 33.00 |
Ask | 43.00 |
Strike | 890.00 |
Expiry date | 2025-12-19 |
Day's range | 49.50 - 49.74 |
Contract range | N/A |
Volume | |
Open interest | 55 |
Most readers would already be aware that Regeneron Pharmaceuticals' (NASDAQ:REGN) stock increased significantly by 20...
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when Regeneron (REGN) reports second-quarter 2024 results.